The vascular barrier that separates blood from tissues is actively regulated by the endothelium and is essential for transport, inflammation, and haemostasis 1 . Haemodynamic shear stress plays a critical role in maintaining endothelial barrier function 2 , but how this occurs remains unknown. Here we use an engineered organotypic model of perfused microvessels to show that activation of the transmembrane receptor NOTCH1 directly regulates vascular barrier function through a non-canonical, transcriptionindependent signalling mechanism that drives assembly of adherens junctions, and confirm these findings in mouse models. Shear stress triggers DLL4-dependent proteolytic activation of NOTCH1 to expose the transmembrane domain of NOTCH1. This domain mediates establishment of the endothelial barrier; expression of the transmembrane domain of NOTCH1 is sufficient to rescue defects in barrier function induced by knockout of NOTCH1. The transmembrane domain restores barrier function by catalysing the formation of a receptor complex in the plasma membrane consisting of vascular endothelial cadherin, the transmembrane protein tyrosine phosphatase LAR, and the RAC1 guanidine-exchange factor TRIO. This complex activates RAC1 to drive assembly of adherens junctions and establish barrier function. Canonical transcriptional signalling via Notch is highly conserved in metazoans and is required for many processes in vascular development, including arterialvenous differentiation 3 , angiogenesis 4 and remodelling
, the mechanisms that link haemodynamic shear stress to the regulation of endothelial cell-cell junctions and vascular permeability remain unknown.
In vivo mechanistic studies of the influence of shear stress on the vascular barrier are challenging, because control over pressures and flows is limited, and the effects of shear stress cannot be decoupled from changes in nutrient exchange. In vitro approaches have enabled better control of these forces, but the use of stiff, planar substrates for cell culture artificially influences cell-extracellular matrix (ECM) and cell-cell adhesion signalling. We therefore developed human engineered microvessels (hEMVs), a biomimetic model of the microvasculature consisting of a lumen surrounded by ECM, lined with human dermal microvascular endothelial cells (Fig. 1a) , and connected to a microflui dic device to enable precise control of perfusion and haemodynamic stresses. This simplified model lacks other cell types such as pericytes or tissue-specific parenchyma, and therefore focuses on autonomous functions of the endothelium. Consistent with in vivo observations 2 , the endothelial lining of hEMVs in the absence of flow was leaky, allowing fluorescently labelled 70-kDa dextran to diffuse from the lumen into the interstitial matrix, whereas steady perfusion at flow rates that impart physiological shear stress to the endothelial cells (> 3 dyn cm −2 ) promoted the establishment of a functional vascular barrier that was resistant to leakage and sensitive to known permeability factors (Fig. 1b, c , Extended Data Fig. 1a-e) .
Shear stress regulates numerous mechanosensitive pathways whose signatures can be inferred from the upregulation of various genetic networks both in vivo and in vitro 10 . We observed increased expression of many such genes in our hEMV system, but noted numerous genes associated with Notch signalling, including those encoding the NOTCH1 ligand DLL4 and the downstream targets of NOTCH1 activation HES1 and HEY1 (Fig. 1d, Extended Data Fig. 2 ). Activation of Notch signalling by shear stresses has recently been shown in zebrafish 11 , so to investigate whether Notch signalling was also involved in shearinduced barrier function in the hEMV system, we treated hEMVs with DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butylester), an inhibitor of γ -secretase 4 , which cleaves NOTCH1 to release the transcriptionally active intracellular domain (ICD) of NOTCH1 (Extended Data Fig. 3a ) 12 . Cleavage of ICD from NOTCH1 increased with flow ( Fig. 1e) , and treatment with DAPT in the presence of shear increased permeability (Fig. 1f) . Conversely, directly activating NOTCH1 by coating the ablumenal surface of the microvessel with recombinant DLL4 (rDLL4, Extended Data Fig. 3a , b) before cell seeding reduced permeability even in static (no flow) conditions (Fig. 1f) . Examination of the endothelium confirmed that shear stress reduced permeability by inducing the assembly of adherens junctions containing vascular endothelial (VE)-cadherin (encoded by CDH5) and the redistribution of F-actin to the cortical membrane (Fig. 1g, h ). The integrity of this organization was disrupted by DAPT (Fig. 1g, h ), and NOTCH1 activation by rDLL4 phenocopied the shear-induced phenotype (Extended Data Fig. 3c ).
Canonical Notch signalling occurs through ICD-dependent transcription of downstream Notch target genes 13 . To identify the role of Notch transcriptional signalling in regulating barrier function, we seeded hEMVs with cells expressing a dominant-negative form of the Notch transcriptional co-factor mastermind-like protein 1 Letter reSeArCH (DN-MAML) 14 . Unexpectedly, DN-MAML expression did not affect permeability (Fig. 1i) or adherens junction formation (Fig. 1j , k, Extended Data Fig. 3d ), despite inhibiting Notch transcriptional signalling (Extended Data Fig. 3e ). To investigate potential non-canonical mechanisms by which Notch activity could regulate barrier function, we generated hEMVs with cells harbouring CRISPR-Cas9-mediated knockout of NOTCH1 and DLL4 (NOTCH1 KO , Extended Data Fig. 3f ; DLL4 KO , Extended Data Fig. 4a) Fig. 3 . In a-k, n ≥ 3 independent hEMVs, mean ± s.e.m. l, Heat maps of Evans blue fluorescence in the mouse dermal vasculature 30 min and 60 min after intravenous co-injection with DAPT or DMSO vehicle control. m, Quantification of diffusive permeability of Evans blue diffusion into the dermal interstitial space (n = 15 vessels across 3 mice per condition). n, Lungs harvested from mice killed 30 min after intravenous injection of Evans blue. o, Vascular permeability was quantified by eluting and measuring the concentration of dye in the lungs relative to the concentration in the blood (n = 4 age and sex-matched littermates; colour-coded, two-way ANOVA). p, Whole-mount lung vasculature immunostains showing leaked Evans blue and stained with DAPI. * P < 0.05, * * P < 0.01; exact P and n values are shown in Source Data; all images are representative of at least three independent experiments.
Letter reSeArCH treatment, resulting in increased permeability (Fig. 1i ) and impaired adherens junction integrity (Fig. 1j , k, Extended Data Fig. 3h-j) without affecting total VE-cadherin levels (Extended Data Fig. 3j ) or cell proliferation (Extended Data Fig. 3k, l) . DLL4 was also required for flowinduced barrier formation (Fig. 1i) , cleavage of the ICD from NOTCH1 (Extended Data Fig. 4a ) and adherens junction formation (Extended Data Fig. 4b, c) . Shear stress has been reported to elevate endocytosis in endothelial cells 15 , and internalization of DLL4 appears to be necessary for ligand-mediated NOTCH1 activation 16 . We found that flow induced dynamin-dependent internalization of DLL4 (Extended Data Fig. 4d-f) , and that chemical inhibition of dynamin reduced DLL4 internalization and abrogated barrier function (Extended Data Fig. 4g ). To validate the finding that Notch activation regulates barrier function, we examined the role of Notch signalling in barrier maintenance in vivo. DAPT was co-injected intravenously with Evans blue dye into six-to-eight-week-old BALB/c nude mice, and dermal vascular permeability was quantified in real time using intravital microscopy ( Fig. 1l, m) . Inhibition of Notch signalling with DAPT significantly increased vascular permeability (Fig. 1l, m, Extended Data Fig. 5a ). The implication that Notch might regulate barrier function via a transcriptionally independent pathway was consistent with the observation that DAPT increased vascular permeability within 15-60 min in vivo (Fig. 1l ) and in vitro (Extended Data Fig. 6a ). This response is likely to be too rapid to be a transcription-dependent response. In vivo, knockout of endothelial NOTCH1 resulted in loss of barrier function, increasing vascular permeability in the lung, as assessed by extravasation of Evans blue 17 ( Fig. 1n-p, Extended Data Fig. 5b ). Together, these results suggest that shear stress has an important role in maintenance of endothelial integrity, and that NOTCH1 might regulate this effect through a non-transcriptional mechanism. Upon NOTCH1 activation, the extracellular domain (ECD) of NOTCH1 is cleaved, which allows γ -secretase-mediated cleavage of the ICD, leaving the transmembrane domain (TMD) in the plasma membrane 18 . Given the observed increase in ICD cleavage with flow, we generated a library of CRISPR-Cas9-mediated NOTCH1 truncation mutants and recombinant rescue constructs (Fig. 2a, Extended Data  Fig. 6e ) to determine whether these subdomains of NOTCH1 contributed to the regulation of vascular permeability. Truncation of the ICD (ICD KO) resulted in constitutively low permeability and elaborated adherens junctions (Fig. 2b-d ) in static conditions, while truncation of both the ICD and the TMD (ICD-TMD KO) increased permeability under flow (Fig. 2b) . These data suggest that the ICD is not critical for NOTCH1-induced barrier function, whereas the TMD is essential. Indeed, expression of the TMD alone or of TMD-ICD in NOTCH1 KO cells rescued barrier function and adherens junction assembly ( Fig. 2e-g ). NOTCH1
KO cells expressing TMD-ICD containing a point mutation that prevents cleavage of the ICD 19 (V1754G, Extended Data Fig. 6b ) failed to rescue barrier function (Fig. 2e) ; and TMD-ICD failed to rescue barrier function in the presence of DAPT, while cells expressing the TMD alone maintained barrier function irrespective of whether they were treated with DAPT (Fig. 2h) . Together, these findings are consistent with a model in which the TMD is the essential domain of NOTCH1 for regulating barrier function, and the barrier-forming activity of the TMD requires cleavage of the ICD from 
Relative junction area KO cells expressing either mApple or TMD-mApple, co-stained for VE-cadherin. Co-localization of the NOTCH1 TMD and VE-cadherin (red arrow) is lost at free edges (blue arrow). j, Immunoprecipitation of VE-cadherin and N-cadherin from NOTCH1 KO cells expressing either mApple or TMD-mApple. Immunoblotting with an RFP antibody identified TMD-mApple in the immunoprecipitates. For all plots, mean ± s.e.m., n ≥ 3 independent hEMVs, * P < 0.05, * * P < 0.01. Exact P and n values are shown in Source Data, all images are representative of at least three independent experiments.
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NOTCH1. To our knowledge, the NOTCH1 TMD has not previously been demonstrated to have a biological function.
To investigate the mechanism by which the NOTCH1 TMD contributes to adherens junction assembly, we expressed mApple-tagged TMD in endothelial cells. TMD-mApple localized to cell-cell junctions containing VE-cadherin, and this localization was lost in cells deficient in VE-cadherin ( Fig. 2i ; Extended Data Fig. 6c, d ). VE-cadherin coimmunoprecipitated with NOTCH1 (Extended Data Fig. 6f ), and the NOTCH1 TMD specifically co-immunoprecipitated with VE-cadherin, but not with neural (N)-cadherin (encoded by CDH2; Fig. 2j ), and that this interaction was mediated, in part, by a six-amino-acid stretch in the N-terminal ectodomain of the TMD (Extended Data Fig. 6g, h ). These data suggest that the NOTCH1 TMD mediates a specific interaction between NOTCH1 and VE-cadherin.
A possible mechanism by which the NOTCH1 TMD regulates cellcell junction assembly was suggested by the reduced cortical actin and increased actin stress fibres in NOTCH1 KO cells (Fig. 3a, b) . The Rhofamily GTPases are powerful regulators of actin redistribution and barrier function 20 , and RAC1 can stabilize adherens junctions by promoting the formation of cortical actin bundles 21 . Indeed, NOTCH1 KO cells and endothelial cells treated with DAPT exhibited reduced RAC1 activity (Fig. 3c, d, Extended Data Fig. 7a, b) , while expression of the NOTCH1 TMD increased RAC1 activity (Fig. 3e, f) . RAC1 activity increased with flow (Extended Data Fig. 7c ), and this increase in RAC1 activity was abrogated by genetic deletion of NOTCH1 or DLL4 (Extended Data Fig. 7d, e) . NOTCH1 KO cells expressing the NOTCH1 TMD and treated with the RAC1 inhibitor NSC 23766 had increased permeability (Fig. 3g) , demonstrating that RAC1 activity was required for barrier function.
To investigate the molecular intermediaries by which NOTCH1 regulates RAC1, we used immunoprecipitation to identify several proteins that interact with VE-cadherin. Only one of these partner proteins, the transmembrane protein tyrosine phosphatase LAR (encoded by PTPRF), dissociated from VE-cadherin in NOTCH1 KO cells (Extended Data Fig. 8a) . Notably, LAR has been reported to bind the RAC1 guanine-exchange factor (GEF) TRIO (also known as triple functional domain protein 22 ) , which has been shown to play a role in Notch-mediated axon guidance in Drosophila 23 . Here we demonstrate that LAR mediates a NOTCH1-dependent interaction between TRIO and VE-cadherin (Extended Data Fig. 8b ). Under static conditions, full-length NOTCH1 was associated with VE-cadherin (Fig. 3h) . Flow-induced activation of NOTCH1 released both the KO cell lysates using the recombinant p21-binding domain of PAK1 (GST-PBD). d, Quantification of band intensity from c revealed a decrease in RAC1 (~ 50%) after knockout of NOTCH1 (n = 3 independent lysates). e, Active RAC1 was isolated using GST-PBD from lysates of NOTCH1 KO cells expressing mApple or TMD-mApple. f, Quantification of band intensities from e shows an increase in RAC1 (~ 45%) with expression of TMD-mApple (n = 3 independent lysates). g, Diffusive permeability of NOTCH1 KO endothelial cells expressing TMD-mApple or mApple control in the presence of 50 μ M NSC 23766 (a RAC1 inhibitor) or vehicle control. h, Immunoprecipitation of VE-cadherin and TRIO from endothelial cells cultured in static or flow conditions. Co-immunoprecipitation of mechanosensory complex proteins was assessed by immunoblotting for NOTCH1 ECD, NOTCH1 ICD, LAR (85 kDa P subunit) and VE-cadherin. KO and scramble control cells cultured under static conditions expressing TMD-mApple or mApple infection control. For g, j, n, n ≥ 3 hEMVs. All plots, mean ± s.e.m., * P < 0.05, * * P < 0.01. Exact P and n values are shown in Source Data. All images are representative of at least three independent experiments.
Letter reSeArCH ECD and the ICD from VE-cadherin and stimulated the interaction of VE-cadherin with LAR and TRIO (Fig. 3h) . The formation of the LAR-TRIO-VE-cadherin complex was NOTCH1-dependent in vitro (Fig. 3i) and in vivo (Extended Data Fig. 8c, d) . Using a VE-cadherin biotin ligase proximity-labelling construct 24 , we confirmed that the association of ICD with VE-cadherin decreased, and the interaction between TRIO and VE-cadherin increased, with NOTCH1 stimulation (Extended Data Fig. 8e, f) . Furthermore, LAR and TRIO are required for the establishment of barrier function, as shown by the reduced RAC1 activity (Extended Data Fig. 7e ), high permeability (Fig. 3j) , and lack of adherens junctions (Fig. 3k, l) in PTPRF KO and TRIO KO hEMVs. Expression of the TMD rescued the interaction of LAR and TRIO with VE-cadherin (Fig. 3m) , and LAR and TRIO were required for NOTCH1 TMD-mediated rescue of barrier defects (Fig. 3n) . Thus, cleavage of the ICD from NOTCH1 releases the TMD, enabling it to assemble a complex containing VE-cadherin, LAR, and TRIO, thereby inducing RAC1 activity to assemble junctions and establish barrier function (Extended Data Fig. 9) .
Notch signalling is a central regulator of many developmental and homeostatic processes, but its diverse effects have been difficult to explain through just the one canonical pathway involving ICD-dependent transcription of Notch target genes 13 . Here, we have demonstrated that receptor cleavage induced by NOTCH1 activation also brings into play the TMD, which promotes association among transmembrane receptors and signalling molecules and acts as a focal point in a pathway that regulates junction assembly and vascular barrier function. Recent work has shown that interactions between the transmembrane domains of other surface receptors drive signalling in diverse biological contexts 25 , suggesting that this is a general mechanism for controlling complex formation at the cell surface.
In the context of Notch, this cortical signalling pathway may explain why human mutations in the Notch receptor family cause vascular defects and barrier dysfunction in human diseases such as CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), Adams-Oliver syndrome and Alagille syndrome [26] [27] [28] , and why inhibition of Notch signalling to treat tumours appears to trigger oedema 29 . Identifying ways to isolate the cortical pathway of Notch from the transcriptional pathway may provide new opportunities to control these devastating complications. Furthermore, quantitative differences in expression of Notch and DLL4 in different vascular beds, described as a key mechanism for tip-stalk cell specification in angiogenesis 30 , may underlie differences in shear sensitivity and baseline permeability in organ-specific vascular beds. More broadly, the combination of a non-canonical pathway that regulates adhesive and cytoskeletal processes together with a transcriptional regulator of cell-fate programs, channelled through a single receptor, provides a new framework for understanding coordinated developmental programs such as stem-cell differentiation and tissue morphogenesis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Cell culture. Human dermal microvascular endothelial cells (hMVEC-Ds, Lonza) were maintained in EGM2-MV growth medium (Lonza) and used at passages 2-10. Human HEK293T cells (Clonetech) were cultured in DMEM (Hyclone) supplemented with 10% fetal bovine serum (Hyclone), 100 U ml −1 penicillin, 100 μ g ml −1 streptomycin (Life Technologies) and 2 mM l-glutamine (Life Technologies). Both cell types were maintained at 37 °C in 5% CO 2 in a humidified incubator. Cell-line authentication (performance, differentiation, and STR profiling) was provided by Lonza and Clontech. Mycoplasma testing was performed on all lines using the PlasmoTest mycoplasma detection kit from InvivoGen. Microfluidics. Microfluidic devices were fabricated using soft lithography. Polydimethylsiloxane (PDMS, Sylgard 184, Dow-Corning) was mixed at a ratio of 10:1 (base:curing agent) and cured overnight at 60 °C on a silicon master. The PDMS was cut from the silicon master, trimmed, and surface-activated by plasma treatment for 1 min. Devices were then bonded to glass and treated with 0.01% poly-l-lysine and 1% glutaraldehyde, washed in sterile water overnight, and sterilized with 70% ethanol for 30 min. Steel acupuncture needles (160 μ m diameter, Seirin) were introduced into each device, and the devices were UV-sterilized for 20 min. Collagen type I (Thermo Fisher scientific) solution was buffered with 10× DMEM, titrated to a pH of 8.0 with NaOH, and brought to a final concentration of 2.5 mg ml −1 collagen I. The collagen solution was injected into the microfluidic devices and polymerized for 20 min at 37 °C. Growth medium was then added to the devices overnight and the needles were removed to create 160 μ m-diameter channels in the collagen gel. hMVECs were harvested with 0.05% Trypsin-EDTA and centrifuged at 200g for 5 min. Cells were resuspended at 0.5 × 10 6 cells ml
in EGM2-MV, 70 μ l of cell suspension was introduced into the devices and cells were allowed to adhere to collagen for 15 min before washing with growth medium. To coat collagen with DLL4, 100 μ l of 1 μ g ml −1 recombinant human DLL4 (R&D Systems) in PBS was introduced into devices and incubated on a rocker at 37 °C overnight. Devices were washed two times with PBS before seeding with cells.
To quantify vascular permeability in the microfluidic device, fluorescent dextran (70 kDa Texas Red or 70 kDa Oregon Green, Thermo Fisher) was introduced into perfusion medium at a concentration of 12.5 μ g ml −1 , and diffusion of the dextran was imaged in real time with a Yokogawa CSU-21-Zeiss Axiovert 200M inverted spinning-disk microscope with a 10× air objective and an Evolve EMCCD camera (Photometrics). Time-lapse microscopy was used to measure the flux of dextran into the collagen gel, and the resulting diffusion profile was fitted to a dynamic mass-conservation equation as previously described 31 , with the diffusivepermeability coefficient (P D ) defined by J = P D (c vessel − c ECM ), where J is the mass flux of dextran, c vessel is the concentration of dextran in the vessel, and c ECM is the concentration of dextran in the perivascular ECM.
To measure the effects of known permeability-inducing factors, flow imparting 5 dyn cm −2 wall shear stress was applied overnight and either VEGF (40 ng ml −1 , 1 h before permeability assay; R&D Systems) or thrombin (1 U ml −1 , 15 min before permeability assay; Sigma) was added. For barrier-enhancing factors, devices were left under static conditions overnight in growth medium, which was supplemented with 10 μ M SU-5416 (Cayman Chemical) or 500 nM S1P (Cayman Chemical) 1 h before the permeability assay. To inhibit endocytosis in the presence of flow, devices were incubated in static conditions in medium supplemented with 60 μ M Dynasore hydrate (Sigma) for 30 min before applying flow at 5 dyn cm −2 overnight in medium supplemented with 60 μ M Dynasore. Measurement of vascular permeability in vivo. All in vivo animal studies were reviewed and approved by the Institutional Animal Care and Use Committees of Boston University and Yale University. Mice were bred and maintained under specific-pathogen-free conditions at the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International)-accredited Boston University and Yale University facilities, and housed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals. For intravital measurements of vascular permeability, mice (six-to-eight-week-old female BALB/c nude mice, CrTac:NCr-Foxn1 nu strain) were anaesthetized using an isoflurane nebulizer, injected retro-orbitally with 100 μ l Evans blue dye (10 mg ml −1 in saline) containing either DMSO or DAPT (20 μ M), and immobilized on a microscope stage in an imaging chamber equilibrated to 37 °C (Extended Data Fig. 10a ). Vascular-permeability images were acquired with a Leica HC FLUOTAR L 25× /0.95 W immersion objective on an upright Leica TCS SP8 multiphoton microscope equipped with a Spectra-Physics Insight DS+ laser tuned to 950 nm excitation and non-descanned emission detection at 680 nm. Vascular permeability was assessed from 20 min post-injection at 5 min intervals until 1 h post-injection. P D was measured for five vessels per field of view as described above.
For bulk-tissue vascular-permeability measurements, inducible NOTCH1 endothelial cell knockout mice (Cdh5-cre ) were used as controls. Cre was induced by injecting four-week-old mice intraperitoneally with tamoxifen (0.2 mg day −1 ) for five consecutive days. Two weeks after the start of Cre induction, 100 μ l Evans blue dye (10 mg ml −1 in saline) was injected retro-orbitally. Thirty minutes post-injection, animals were euthanized by cervical dislocation under anaesthesia, and blood and tissue samples were harvested, including the lungs. Blood samples were clarified at 14,000 r.p.m. for 5 min at 4 °C; freeze-dried lung samples were weighed and incubated with 500 μ l formamide at 56 °C for 48 h and clarified by centrifugation. Optical density was measured at 620 nm (for Evans blue) and 740 nm (haem) using a SpectraMax M5 spectrophotometer (Molecular Devices), and the concentrations of Evans blue were calculated using the standard curve of serial dilutions of Evans blue in formamide. Levels of Evans blue in tissues were normalized by tissue weight and concentration of Evans blue in blood, and corrected for haem pigment contamination. Antibodies and reagents. Antibodies against TRIO (H-120, 1:500), NOTCH1 ICD (C-20-R, 1:1000), NOTCH1 ECD (H-131, 1:500), VE-cadherin (F-8, 1:200) and VE-PTP (H-300, 1:250) were from Santa Cruz Biotechnology. Antibodies against VE-cadherin (ab33168, 1:2,000), RFP (ab124754, 1:1000) and β -tubulin (ab6046, 1:5,000) were from Abcam. Antibodies against VEGFR2 (55B11, 1:1000), NOTCH1 V1754G (D3B8, 1:1000 WB) and haemagglutinin (6E2, 1:1000 WB, AF647 conjugate IF) were from Cell Signaling Technologies. RAC1 antibody (102, 1:1,000) was from BD Biosciences. Rhodamine and Alexa Fluor 488-labelled phalloidin, and Alexa Fluor 488, 568 and 647 goat anti-mouse and anti-rabbit IgG secondary antibodies were from Life Technologies. HRP-conjugated donkey antimouse, anti-rabbit, and anti-goat IgG secondary antibodies were from Fitzgerald. PTPRF antibody (SAB4200321, 1:1,000), DAPI, DAPT, Evans blue dye, and formamide were from Sigma. The RAC1 inhibitor NSC 23766 was from Santa Cruz Biotechnology. Cloning and qPCR. Human CDH5 (gift from M. Davidson) and human NOTCH1 (gift from M. Elowitz) cDNAs were used to make C-terminal mApple-tagged constructs in a modified pRRL lentiviral expression vector. PCR amplification of the following amino acid sites was used to make C-terminal mApple-tagged NOTCH1 truncation constructs: TMD-ICD-mApple (S2 cleavage site to end of ICD, Val1721-Lys2555) and TMD-mApple (S2 to S3 cleavage site, Val1721-Gly1753). The DN-MAML construct (MSCV-IRES-GFP MAML1 13-74) was from J. Aster. Human DLL4 cDNA (Sino Biological) was modified with an N-terminal haemagglutinin tag by PCR and cloned into a modified pRRL lentiviral expression vector. All constructs were expressed by lentiviral transduction.
Endothelial cells were lysed with Trizol (LifeTechnologies) followed by chloroform phase separation. The aqueous phase was diluted with 70% ethanol at a 1:1 ratio, loaded on an RNA micro column (RNA microkit, Qiagen SciencesSA) and RNA extraction was performed according to the manufacturer's protocol. Subsequently, 1 μ g total RNA was converted to cDNA with qScript cDNA Supermix (Quanta Sciences). Real-time PCR was performed in 20-μ l reactions using the SYBR Green Mastermix I (Roche) and a LightCycler480 (Roche), with 40 cycles of 95 °C for 3 s, 60 °C for 10 s and 72 °C for 20 s. Specific gene targets were detected with the primers listed in Supplementary Table 1. Primers for NOTCH1 and DLL1 were acquired from Qiagen (Quantitec Hs_NOTCH1_2_SG, Quanititec Hs_DLL1_1_SG).
Relative gene expression is expressed as -Δ Δ C t , in which Δ C t is the difference in C t value between the gene of interest (GOI) and a housekeeping gene (proteasome subunit beta type-2 (PSMB2) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) and Δ Δ C t is the difference between the Δ C t of the GOI in an experimental condition and the Δ C t of the same GOI in a control condition. Heat maps showing -Δ Δ C t of the GOI under flow normalized to static controls were generated using Genesis v1.8.1
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. Primer sequences for qPCR are shown in Supplementary Table 1 . Lentiviral-mediated CRISPR genome editing. Stable CRISPR-knockout primary hMVEC-D cell lines in were generated using the lentiCRISPRv2 system (gift from F. Zhang, Addgene plasmid #52961). Specific guide (g)RNAs were generated using the Optimized CRISPR Design tool (F. Zhang) and cloned into the BsmBI site of plentiCRISPRv2. gRNAs used for both silencing and truncation of genomic targets are summarized in Supplementary Table 2 . Individual gRNA-containing plentiCRISPRv2 plasmids were co-transfected with pVSVG, pRSV-REV, and pMDLg/pRRE packaging plasmids into HEK-293T cells using calcium phosphate transfection. After 48 h, viral supernatants were collected, concentrated using PEG-IT viral precipitator (SBI), and resuspended in PBS. hMVEC-Ds were transduced in growth medium overnight and medium was replaced the following morning. At 48 h after infection, cells were plated in 6-well plates at 75,000 cells per well and selected with 2 μ g ml −1 puromycin for 3-4 days. All CRISPR modifications were verified by western blot. GTPase activity assays. The pGEX4T-1 construct containing the p21-binding domain of PAK1 (PBD) was from Addgene (Plasmid 12217). In brief, expression Letter reSeArCH of the GST fusion protein in BL21 Escherichia coli was induced with 200 μ M isopropyl-β -d-thiogalactoside (IPTG) for 12-16 h at room temperature. Bacterial cells were lysed in buffer containing 25 mM HEPES pH 7.6, 1% Triton X-100, 150 mM NaCl, 5 mM MgCl 2 , 1 mM dithiothreitol, and protease and phosphatase inhibitor cocktails (Roche), and the proteins were purified by incubation with glutathione-Sepharose 4B beads (GE Healthcare) at 4 °C. For active RAC1 pulldowns, confluent hMVEC-Ds plated on 50 μ g ml −1 collagen I in reduced serum growth medium (0.5% FBS) were rinsed with cold PBS containing 1 mM Ca 2+ and 0.5 mM Mg 2+ (PBS+ ), then lysed with cold 50 mM Tris pH 7.6, 200 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 5 mM MgCl 2 , and protease and phosphatase inhibitor cocktails, sonicated at 3 W on ice for 5 s, and clarified at 14,000g for 5 min. Lysates were equalized for protein content and volume and rotated at 4 °C for 1 h with 20 μ g GST-PBD. Bead pellets were washed three times with lysis buffer, extracted in 2× NuPAGE LDS sample buffer (Life Technologies) containing 100 mM DTT, and analysed by SDS-PAGE and immunoblotting with chemiluminescent HRP detection. Western blots were adjusted for brightness and contrast using ImageJ. Active RAC1 quantifications were normalized to total RAC1 for each condition. Immunoprecipitation. Confluent hMVEC-Ds plated on 50 μ g ml −1 collagen I and cultured in growth medium were rinsed with cold PBS+ , then lysed with cold 25 mM HEPES, pH 7.5, 200 mM NaCl, 1% Triton X-100, 5 mM MgCl 2 , and 1.5× protease and phosphatase inhibitors (Roche). Lysates were drawn through a 21G syringe 15 times and incubated on ice for 30 min before clarification at 14,000g for 15 min at 4 °C. Clarified lysates were equalized for protein content and volume and incubated with 2 μ g of anti-VE-cadherin, 2 μ g of anti-TRIO, or 2 μ g anti-NOTCH1 antibodies at 4 °C with end-over-end rotation. Antibody complexes were purified with Protein A/G beads (Life Technologies) at 4 °C with end-over-end rotation. Bead pellets were washed three times with lysis buffer. Protein complexes were extracted in 2× NuPAGE LDS Sample Buffer (Life Technologies) containing 100 mM DTT and analysed by SDS-PAGE and immunoblotting with chemiluminescent HRP detection. Western blots were adjusted for brightness and contrast using ImageJ.
For immunoprecipitation of VE-cadherin and Trio from mouse lung lysates, age and sex-matched Cdh5-cre :Notch1 fl/fl littermates were euthanized by cervical dislocation under anaesthesia and lungs were removed and immediately snap frozen in liquid nitrogen. Mouse lungs were homogenized in a Potter-Elvehjem tissue grinder in lysis buffer (25 mM HEPES pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-40, and 1.5× protease and phosphatase inhibitor cocktail (ThermoFisher)), and clarified by centrifugation at 20,000g for 30 min at 4 °C. The soluble supernatants were pre-cleared with protein-G sepharose beads and then incubated with protein-G sepharose beads with VE-cadherin or Trio antibody (Santa Cruz, 1 mg) for 3 h at 4 °C, washed three times with lysis buffer and then processed in SDS-PAGE sample buffer. Immunofluorescence. For morphological analysis of adherens junctions and actin cytoskeleton, cells cultured in complete medium were permeabilized and fixed with 1% paraformaldehyde, 0.03% Triton X-100 in PBS+ at 37 °C for 90 s, and immediately post-fixed in 4% paraformaldehyde in PBS+ at 37 °C for 15 min. The cells were rinsed three times with PBS+ and permeabilized with 0.5% Triton X-100 in PBS+ for 10 min. Cells were blocked with 2% BSA in PBS+ . Primary and secondary antibodies were applied in 2% BSA in PBS+ and rinsed three times over 30 min with PBS+ between each treatment. To examine the localization of endogenous NOTCH1 and TMD-mApple, cells cultured in complete medium were fixed with 4% paraformaldehyde in PBS+ , permeabilized with 0.1% Triton X-100 in PBS+ , and blocked with 2% BSA in PBS+ . Primary and secondary antibodies were applied in 2% BSA in PBS+ and rinsed three times over 30 min with PBS+ between each treatment. For live-cell or immunofluorescent imaging, images were acquired with a Yokogawa CSU-21/Zeiss Axiovert 200M inverted spinning disk microscope with either a Zeiss LD C-Apochromat 40× , 1.1 N.A. or 63× , 1.15 N.A. water-immersion objective and an Evolve EMCCD camera (Photometrics). Fluorescence images were adjusted for brightness and contrast using ImageJ and MATLAB software.
To quantify junctional organization, greyscale micrographs of cells immunostained for VE-cadherin were converted to black and white based on a threshold determined by Otsu's method, and junctional area was defined as the total number of pixels above the threshold. To quantify actin stress fibres and cortical actin, the intensity of Alexa Fluor 488 phalloidin-labelled cells was plotted along lines drawn between the centroids in the nuclei of neighbouring cells. Local intensity peaks were measured to determine stress fibre locations (Extended Data  Fig. 10b ). Cortical actin was defined as the area under the peak at cell-cell junctions normalized to total area under the curve, and stress fibres were quantified as the number of peaks normalized by the total length of the line between nucleus centroids.
To measure DLL4 endocytosis, endothelial cells expressing haemagglutinin (HA)-tagged DLL4 (DLL4-HA) were seeded into flow chambers (Ibidi) and cultured for 6 h under static conditions. Dynasore hydrate or DMSO-load control was added for 30 min, followed by AlexaFluor 488-conjugated mouse heamagglutinin antibody (1:250) in medium containing Dynasore or DMSO for 30 min before washing with medium containing Dynasore or DMSO. Devices were then cultured in static conditions or under flow imparting 5 dyn cm −2 shear stress for 1 h in medium containing Dynasore or DMSO before fixation with 4% PFA in PBS+ at 37 °C for 15 min. Cells were permeabilized with 0.025% saponin (Sigma) and 2% BSA in PBS+ for 30 min at room temperature, and all subsequent antibody incubations and washes were performed in this buffer. Cells were incubated with anti-NOTCH1 ECD rabbit antibody (1:200) overnight at room temperature before AlexaFluor 488 anti-mouse (1:200) and AlexaFluor 568 anti-rabbit (1:200) antibodies were added for 2 h at 4 °C. The fraction of cells with internalized DLL4 was determined by counting the number of cells with more than one haemagglutinin-positive punctum and the total number of cells labelled by DAPI staining. Statistical analysis. Sample sizes and P values are reported in the figure legends and statistical analyses were performed using GraphPad Prism 6.0 or Microsoft Excel. Unless otherwise noted in the figure legend, statistical differences between sets of data were analysed with a two-tailed, unpaired Student's t-test, and exact P values are provided in the Source Data. Sample sizes of sufficient power were chosen on the basis of similar published research and were confirmed statistically by appropriate tests. Experiments were not randomized and experimenters were not blinded to experimental conditions. Data availability. Graphical Source Data are provided for each figure. The source images for the western blots in the figures are available in the Supplementary Information. Additional data that support the findings of this study are available from the corresponding author upon reasonable request. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. Supplemental Methods, "Statistical Analysis": "Sample sizes of sufficient power were chosen on the basis of similar published research and were confirmed statistically by appropriate tests."
Data exclusions
Describe any data exclusions.
No samples or animals were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Age/sex matched litter mates were assigned to groups by genotype. No randomization was used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
